SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- Neurana Pharmaceuticals, a specialty pharmaceutical company focused on the treatmentof neuromuscular conditions, today announced that it has enrolled its first patient in the "STAR Study," a Phase 2 dose ranging study of tolperisone in acute muscle spasms of the back.
The STAR Study is a double-blind, randomized, placebo-controlled,
"We are very excited to announce the first patient enrolled in the STAR Study," said Craig Thompson, President and Chief Executive Officer of Neurana. "This marks an important achievement in the U.S. clinical development of tolperisone and furthers our aim of providing patients suffering from acute back pain a novel, non-sedating, non-drowsy, non-opioid therapy."
Additional information about the STAR Study, including eligibility criteria and a list of clinical study sites can be found at www.clinicaltrials.gov (NCT Number: NCT03802565)
About TolperisoneTolperisone is a medicine widely prescribed outside of the U.S. for acute muscle spasms and spasticity. In the U.S., tolperisone is being investigated as a novel, non-opioid, non-sedating, non-drowsy muscle relaxant for the relief of pain due to muscle spasm. Tolperisone is predicted to have effective analgesic activity in addition to muscle relaxation because of its centrally-acting dual voltage gated calcium and sodium channel blocker mechanism of action.
About Neurana Pharmaceuticals, Inc. Neurana Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the treatment of neuromuscular conditions, such as acute, painful muscle spasms of the neck and back and spasticity. For additional information please visit us at www.neuranapharma.com.
View original content:http://www.prnewswire.com/news-releases/neurana-pharmaceuticals-announces-first-patient-enrolled-in-the-star-study-a-phase-2-dose-ranging-study-of-tolperisone-in-acute-muscle-spasms-of-the-back-300788715.html
SOURCE Neurana Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!